



IN THE CLAIMS

Claims 1-17 (cancel)


18. (New) A compound of the formula




19. (New) The compound as claimed in claim 18 having the formula




20. (New) The compound as claimed in claim 18 having the formula




21. (New) The compound as claimed in claim 18 having the formula




22. (New) The compound as claimed in claim 18 having the formula




23. (New) The compound as claimed in claim 18 having the formula




24. (New) The compound as claimed in claim 18 having the formula




25. (New) The compound as claimed in claim 18 having the formula




26. (New) The compound as claimed in claim 18 having the formula




27. (New) The compound as claimed in claim 18 having the formula




28. (New) A process for the preparation of formula V




which comprises reacting a 4- (1H- benzo[d] imidazol-2-yl) phenol of formula I




with - [4-(n- bromoalkyloxy)-5- methoxy-2- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II



in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {4-(1H- benoz [d] imidazolo- 2 yl) phenoxy] alkyl - oxy- 5 methoxy- 2-nitrobenzoyl} pyrrolidine-2- carboxaldehyde diethyl thioacetal III




where "n" is 3 to 5, reducing said compound of formula III with $SnCl_2 \cdot 2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating the (2S) -N- {n- 4- (1H- benzo [d] imidazolo- 2yl)phenoxy]alkyl]-oxy-5-methoxy-2-aminobenzoyly} pyrrolidine- 2- carboxaldehyde diethyl thioacetal of formula IV




where n is 3 to 5 by known methods, reacting the compound of formula IV with a deprotecting agent to obtain a compound of formula V, wherein n is as defined above.


29. (New). A process for the preparation of a compound of formula IX




which comprises reacting a 4- [6-4-. methylhexahydro- 1- pyrazinyl)- 1H - benzo [imidazol- 2- yl] phenol VI




with N-[4-(n-bromoalkyloxy)-5- methoxy-2-nitrobenzo-yl]pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II




in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {n- (4- [6-4- methylhexahydro-1- pyrazinyl]- 1H- benzo [d] imidazol- 2-yl] phenoxy] alkyl-oxy- 5- methoxy-2- nitrobenzoyl pyrrolidine-2- carboxaldehyde diethyl thioacetal VII




where n is 3 to 5, reducing said compound of formula VII with $SnCl_2O$ in the presence of organic solvent up to a reflex temperature, isolating (2S)-N- {n- (4- [6-(4-methylhexahydro-1- pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenoxy] alkyl)-oxy-5- methoxy -2- aminobenzoyl pyrrolidine-2- carboxaldehyde diethyl thioacetal of formula VIII



in the presence of K_2CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-{n- (4- [6-4- ethylhexahydro-1- pyrazinyl)- H- benzo [d] imidazol-2- yl] phenoxy] alkyl] - oxy- 5- methoxy- 2- nitrobenzoyl) pyrrolidine- 2- carboxaldehyde diethyl thioacetal of formula XI



where "n" is 3 to 5, reducing said compound of formula XI with $SnCl_2 \cdot 2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n-(4-[6-(4-ethylhexahydro-1-pyrazinyl)-1H - benzo[d] imidazol-2- yl] phenoxy] alkyl)- oxy-5- methoxy-2- aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal of formula XII where n is 3 to 5



and reacting the amino compound of formula XII with a deprotecting agent to produce the compound of formula XIII wherein n is as defined above.

31. (New) A composition comprising a compound according to claim 1 and an excipient.

32. (New). A method for treating a mammal comprising administering an effective amount of

a compound according to claim 1 to the mammal wherein the mammal has at least one cancer selected from the group consisting of leukemia, non-small cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate and breast cancer.

34. (New) A method for treating a mammal comprising administering an effective amount of a composition according to claim 32 to the mammal wherein the mammal has at least one cancer selected from the group consisting of leukemia, non-small cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate and breast cancer.

35. (New) The method according to claim 33 wherein the mammal is a human.

36. (New) The method according to claim 34 wherein the mammal is a human.